Abstract
Objective
To explore the effects of renal function estimated by measured creatinine clearance (ClCR) on trough serum concentration (Cmin) of piperacillin given to critically ill patients.
Design
Prospective observational study.
Setting
An intensive care unit and research ward in a university hospital.
Patients
Seventy critically ill patients, including 22 with severe trauma.
Interventions
All subjects received an intravenous infusion of piperacillin 4 g three times (n = 61) or four times (n = 9) per day. Piperacillin Cmin values were determined 24 h after treatment started and compared to the French breakpoint defining antibiotic susceptibility against Enterobacteriaceae (8 mg/l) or Pseudomonas sp. (16 mg/l).
Results
Median (range) piperacillin Cmin was 11.9 (< 1–156.3) mg/l, with a great variability among patients. Although the median value was close to the breakpoints, sub-therapeutic plasma levels were frequently observed. Piperacillin Cmin was lower than the breakpoint for Enterobacteriaceae in 37% of patients, and lower than the breakpoint for P. aeruginosa in 67% of them. A strong relationship was observed between piperacillin Cmin and ClCR: the higher the ClCR, the lower the piperacillin Cmin in serum. For patients with a ClCR < 50 ml/min, enough piperacillin Cmin was achieved in most patients with 12 g piperacillin per day. For patients with higher ClCR values, a piperacillin daily dose of 16 g or more may be warranted.
Conclusions
In critically ill patients, therapeutic monitoring must be part of the routine, and knowledge of ClCR value may be useful for the choice of adequate initial piperacillin dosing.
This is a preview of subscription content, log in via an institution to check access.
References
Perry CM, Markham A (1999) Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs 57:805–843
Vondracek TG (1995) Beta-lactam antibiotics: is continuous infusion the preferred method of administration? Ann Pharmacother 29:415–424
Craig WA, Ebert SC (1992) Continuous infusion of beta-lactam antibiotics. Antimicrob Agents Chemother 36:2577–2583
Mattoes HM, Capitano B, Kim MK, Xuan D, Quintiliani R, Nightingale CH, Nicolau DP (2002) Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. Chemotherapy 48:59–63
Lipman J, Wallis SC, Rickard C (1999) Low plasma cefepime levels in critically ill septic patients: pharmacokinetic modeling indicates improved troughs with revised dosing. Antimicrob Agents Chemother 43:2559–2561
Hanes SD, Wood GC, Herring V, Croce MA, Fabian TC, Pritchard E, Boucher BA (2000) Intermittent and continuous ceftazidime infusion for critically ill trauma patients. Am J Surg 179:436–440
Mehrotra R, De Gaudio R, Palazzo M (2004) Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Intensive Care Med 30:2145–2156
Brown R, Babcock R, Talbert J, Gruenberg J, Czurak C, Campbell M (1980) Renal function in critically ill postoperative patients: sequential assessment of creatinine osmolar and free water clearance. Crit Care Med 8:68–72
Lipman J, Wallis SC, Boots RJ (2003) Cefepime versus cefpirome: the importance of creatinine clearance. Anesth Analg 97:1149–1154
Ocampo AP, Hoyt KD, Wadgaonkar N, Carver AH, Puglisi CV (1989) Determination of tazobactam and piperacillin in human plasma, serum, bile and urine by gradient elution reversed-phase high-performance liquid chromatography. J Chromatogr 496:167–179
Shikuma LR, Ackerman BH, Weaver RH, Solem LD, Strate RG, Cerra FB, Zaske DE (1990) Effects of treatment and the metabolic response to injury on drug clearance: a prospective study with piperacillin. Crit Care Med 18:37–41
Jehl F, Muller-Serieys C, de Larminat V, Monteil H, Bergogne-Berezin E (1994) Penetration of piperacillin-tazobactam into bronchial secretions after multiple doses to intensive care patients. Antimicrob Agents Chemother 38:2780–2784
Boselli E, Breilh D, Cannesson M, Xuereb F, Rimmele T, Chassard D, Saux MC, Allaouchiche B (2004) Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med 30:976–979
Hyatt JM, McKinnon PS, Zimmer GS, Schentag JJ (1995) The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents. Clin Pharmacokinet 28:143–160
Buck C, Bertram N, Ackermann T, Sauerbruch T, Derendorf H, Paar WD (2005) Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion. Int J Antimicrob Agents 25:62–67
Johnson CA, Halstenson CE, Kelloway JS, Shapiro BE, Zimmerman SW, Tonelli A, Faulkner R, Dutta A, Haynes J, Greene DS, et al. (1992) Single-dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease. Clin Pharmacol Ther 51:32–41
Westphal JF, Brogard JM, Caro-Sampara F, Adloff M, Blickle JF, Monteil H, Jehl F (1997) Assessment of biliary excretion of piperacillin-tazobactam in humans. Antimicrob Agents Chemother 41:1636–1640
Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP (2005) Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 56:388–395
Brunner M, Pernerstorfer T, Mayer BX, Eichler HG, Muller M (2000) Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit Care Med 28:1754–1759
Author information
Authors and Affiliations
Corresponding author
Additional information
No funding source
Rights and permissions
About this article
Cite this article
Conil, JM., Georges, B., Mimoz, O. et al. Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive Care Med 32, 2063–2066 (2006). https://doi.org/10.1007/s00134-006-0421-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-006-0421-1